Tarsus Pharmaceuticals, Inc. (TARS)
| Market Cap | 2.02B |
| Revenue (ttm) | 129.62M |
| Net Income (ttm) | -134.34M |
| Shares Out | 38.23M |
| EPS (ttm) | -3.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 702,547 |
| Open | 50.52 |
| Previous Close | 52.00 |
| Day's Range | 50.20 - 53.62 |
| 52-Week Range | 18.99 - 56.77 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 54.20 (+2.44%) |
| Earnings Date | Nov 13, 2024 |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to addr... [Read more]
Financial Performance
In 2023, Tarsus Pharmaceuticals's revenue was $17.45 million, a decrease of -32.42% compared to the previous year's $25.82 million. Losses were -$135.89 million, 118.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is $54.2, which is an increase of 2.44% from the latest price.
News
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala -...
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created Medical Organization Dr. Yeu transitions from her role as Chief Medical Advisor and Boar...
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr...
Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations
Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is...
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...
Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with ...
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO A...
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre...
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants David Nakasone - Head of Investor Relations Bobby Azamian - Chief Executive Off...
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
Generated $24.7 million in net product sales of XDEMVY ® , an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize trea...
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr...
Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
TARS has reported positive results from three clinical trials of lotilaner in various formulations. TARS plans to discuss the path forward in these new indications with the US Food and Drug Administra...
Tarsus to Participate at Upcoming Investor Conferences
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr...
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease
Tarsus Announces Pricing of $100.0 Million Public Offering
IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new te...
Tarsus Announces Proposed $100.0 Million Public Offering
IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new tec...
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four m...